Aug 18, 2023, 18:03
Aaron Goodman: How to choose between the 2 new BCMA directed bispecifics in myeloma?
Quoting on Aaron Goodman, Hematologist/Bone marrow transplanter at UCSD:
“How to choose between the 2 new (B-cell maturation antigen) BCMA directed bispecifics in myeloma?
Erlantamab is eventually given every 2 weeks as opposed to teclistamab every week for ever.
They will never be compared in RCT and both cost a huge amount of money this is all I have.
So I use erlantamab.”
Source: Aaron Goodman/Twitter